Ophthalmology Innovation Forum: Scaling New Heights in the Industry
As eye health becomes a key component of the “Healthy China” initiative, and with the deepening of healthcare reforms and increased support for ophthalmology, China’s ophthalmic market is exhibiting a trend of “significant growth within a niche sector.”
Focusing on Ophthalmic Diagnosis and Treatment, Digital Health Redefines Solutions for Eye Care. Digital therapeutics empower ophthalmology not only by enabling patient management but also by delivering direct effects, rapid results, and high cure rates. Digital therapeutics hold broad application prospects in ophthalmology, while also creating substantial market space and venture capital opportunities for the eye care industry.
Since 2021, more than 40 companies in the ophthalmology sector have secured financing, with total funds raised exceeding RMB 8 billion, setting a new historical high. According to market size forecasts for ophthalmology by third-party securities institutions, the eye drop market was projected to approach RMB 20 billion in 2020, while the current market size for diagnosis and treatment of eye diseases has already surpassed RMB 20 billion, indicating at least twofold growth potential in the future.
What are the innovative trends in ophthalmology across the three major areas of clinical diagnosis and treatment, optometry, and visual science? What industrial investment opportunities exist within the ophthalmology sector? How can the commercialization process of ophthalmic products be accelerated?Initiated by VCBeat and co-organized by Shijing Medical"Ophthalmology Industry Innovation Forum” event, will soon meet everyone online. This forum brings together top industry leaders and the freshest startup and innovation projects, hopingPresent the most professional and authoritative discussions to help practitioners across the industry value chain and other investors, fromFrom policies to the forefront of scientific research and clinical practice, and then to the most innovative startup solutions, gain a comprehensive understanding of industry dynamics and draw on industry insights.The forum will discuss the three major trends in the ophthalmology industry:
Trend 1: “Gaming + Ophthalmic Care” Adds a BUFF to Digital Health
Since the beginning of 2022, digital therapeutics (DTx) in China have achieved substantial breakthroughs. In terms of regulatory approvals, several DTx products have been approved within a short period. Meanwhile, DTx has been included in provincial-level planning for the first time; the Hainan Provincial Health Commission listed “exploring pilot trials of digital therapeutics” as one of the key tasks in the “14th Five-Year Plan” for Digital Health Development in Hainan Province. Domestic gaming companies have begun to explore the integration of gaming with ophthalmic care, yielding promising results. It is evident that the convergence of digital therapeutics and ophthalmology will remain a noteworthy area of focus for the foreseeable future.
Trend 2: AI-Empowered Smart Healthcare Ushers in New Developments for Intelligent Ophthalmology
“AI+” has sparked another technological revolution following the internet. Over the past year, medical AI products have continuously entered the market. Among these, medical imaging, empowered by AI technology, has gradually evolved from morphological description to in-depth functional research, providing more critical information for clinical diagnostic decision-making. The development of medical imaging AI has also driven growth in multiple niche sectors, such as chest AI and ophthalmic AI. Fundus imaging, due to its significant clinical reference value in the diagnosis and treatment of numerous ophthalmic diseases as well as systemic conditions like hypertension and atherosclerosis, has become a popular—and even preferred—focus area for AI empowerment.
Trend 3: The Wave of Domestic Substitution—Ophthalmic Devices Will Capture a Larger Market Share
For many years, the mid-to-high-end medical devices in China’s ophthalmic equipment sector, such as core medical equipment and high-value medical consumables, have long been monopolized by imported products due to high technical barriers. Nowadays, domestic ophthalmic devices are accelerating innovation and R&D, and import substitution has begun to take off. Some Chinese manufacturers are increasing their investment in scientific research and accelerating their entry into the mid-to-high-end ophthalmic medical device market, achieving significant breakthroughs in fields such as intraocular lenses (IOLs) and contact lenses. The ophthalmic medical device industry is at a critical juncture for replacing imports; the overall industry landscape and unicorn companies have become increasingly prominent, presenting greater opportunities for domestic substitution.
—
Ophthalmology Innovation Forum
Forum Time: Morning of June 15, 2022
Forum Organizers: VB100, VCBeat, Artery Orange, Eggshell Research Institute, Artery New Medicine
Co-organizers:Vision Medical
● 09:00-09:20
Practice of Digital Therapeutics in Clinical Ophthalmology Applications
Wang Lejin | Chief Physician and Professor, Peking University People's Hospital
● 09:20-09:40
A 100-Billion Market, A Golden Track, Winning Through Innovation
——2022 Ophthalmology Industry Research
Wang Shiyu | Senior Researcher, VCBeat
● 09:40-10:00
VCOphthalmology Investment from a Perspective
Liang Yucheng | Head of Digital Therapeutics, Danlu Capital
● 10:00-10:20
How Digital Therapeutics Empower Ophthalmic Diagnosis and Treatment
Zhou Mosheng | Founder and Chairman of Shijing Medical
● 10:20-10:40
Ophthalmic AI Enters the Era of Multi-Disease Applications
Sun Yuhui | Founder and CEO of Zhiyuan Huitu
● 10:40-11:00
Development Strategies and Applications of Innovative Ophthalmic Therapies Across the Full Life Cycle
Dr. Haidi Hu | Founder and CEO of Auright Therapeutics
● 11:00-11:20
Capital Influx, Booming Sector: How to Accelerate the Commercialization of Ophthalmic Products
Tian Bingshi | General Manager, Business Channel Management Division, Huatang Dachang
● 11:20-11:40
Value Upgrades for Private Hospitals Driven by Talent Development and Technological Advancement
Zhang Haozhi | Vice President, Huaxia Eye Hospital Group
● 11:40-12:30
Expert Roundtable: With a Vast Population of Myopia Patients, How Can We Build a Scientific Myopia Prevention and Control System?
Moderator: Liang Yucheng | Head of Digital Therapeutics, Danlu Capital
Zhou Mosheng | Founder and Chairman of Shijing Medical
Wang Lejin | Chief Physician and Professor, Peking University People's Hospital
Ran Maoyue | Vice President, MedSci
Dr. Haidi Hu | Founder and CEO of Auramed Biopharma
Contributing Editor: Guo Ye
—
Scan the QR Code to Join the Future Healthcare 100 Conference Now
